Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model

While vaccines protecting against SARS-CoV-2 infection are approved, currently, there are no drugs suitable for high-risk exposure use against SARS-CoV-2. Here, Rosenke et al. provide evidence that orally delivered MK-4482, a nucleoside analog, inhibits SARS-CoV-2 replication in the Syrian hamster m...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kyle Rosenke, Frederick Hansen, Benjamin Schwarz, Friederike Feldmann, Elaine Haddock, Rebecca Rosenke, Kent Barbian, Kimberly Meade-White, Atsushi Okumura, Shanna Leventhal, David W. Hawman, Emily Ricotta, Catharine M. Bosio, Craig Martens, Greg Saturday, Heinz Feldmann, Michael A. Jarvis
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/9a78a63a312847aa863ae1016f4d581a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9a78a63a312847aa863ae1016f4d581a
record_format	dspace
spelling	oai:doaj.org-article:9a78a63a312847aa863ae1016f4d581a2021-12-02T18:03:25ZOrally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model10.1038/s41467-021-22580-82041-1723https://doaj.org/article/9a78a63a312847aa863ae1016f4d581a2021-04-01T00:00:00Zhttps://doi.org/10.1038/s41467-021-22580-8https://doaj.org/toc/2041-1723While vaccines protecting against SARS-CoV-2 infection are approved, currently, there are no drugs suitable for high-risk exposure use against SARS-CoV-2. Here, Rosenke et al. provide evidence that orally delivered MK-4482, a nucleoside analog, inhibits SARS-CoV-2 replication in the Syrian hamster model.Kyle RosenkeFrederick HansenBenjamin SchwarzFriederike FeldmannElaine HaddockRebecca RosenkeKent BarbianKimberly Meade-WhiteAtsushi OkumuraShanna LeventhalDavid W. HawmanEmily RicottaCatharine M. BosioCraig MartensGreg SaturdayHeinz FeldmannMichael A. JarvisNature PortfolioarticleScienceQENNature Communications, Vol 12, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Kyle Rosenke Frederick Hansen Benjamin Schwarz Friederike Feldmann Elaine Haddock Rebecca Rosenke Kent Barbian Kimberly Meade-White Atsushi Okumura Shanna Leventhal David W. Hawman Emily Ricotta Catharine M. Bosio Craig Martens Greg Saturday Heinz Feldmann Michael A. Jarvis Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model
description	While vaccines protecting against SARS-CoV-2 infection are approved, currently, there are no drugs suitable for high-risk exposure use against SARS-CoV-2. Here, Rosenke et al. provide evidence that orally delivered MK-4482, a nucleoside analog, inhibits SARS-CoV-2 replication in the Syrian hamster model.
format	article
author	Kyle Rosenke Frederick Hansen Benjamin Schwarz Friederike Feldmann Elaine Haddock Rebecca Rosenke Kent Barbian Kimberly Meade-White Atsushi Okumura Shanna Leventhal David W. Hawman Emily Ricotta Catharine M. Bosio Craig Martens Greg Saturday Heinz Feldmann Michael A. Jarvis
author_facet	Kyle Rosenke Frederick Hansen Benjamin Schwarz Friederike Feldmann Elaine Haddock Rebecca Rosenke Kent Barbian Kimberly Meade-White Atsushi Okumura Shanna Leventhal David W. Hawman Emily Ricotta Catharine M. Bosio Craig Martens Greg Saturday Heinz Feldmann Michael A. Jarvis
author_sort	Kyle Rosenke
title	Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model
title_short	Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model
title_full	Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model
title_fullStr	Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model
title_full_unstemmed	Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model
title_sort	orally delivered mk-4482 inhibits sars-cov-2 replication in the syrian hamster model
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/9a78a63a312847aa863ae1016f4d581a
work_keys_str_mv	AT kylerosenke orallydeliveredmk4482inhibitssarscov2replicationinthesyrianhamstermodel AT frederickhansen orallydeliveredmk4482inhibitssarscov2replicationinthesyrianhamstermodel AT benjaminschwarz orallydeliveredmk4482inhibitssarscov2replicationinthesyrianhamstermodel AT friederikefeldmann orallydeliveredmk4482inhibitssarscov2replicationinthesyrianhamstermodel AT elainehaddock orallydeliveredmk4482inhibitssarscov2replicationinthesyrianhamstermodel AT rebeccarosenke orallydeliveredmk4482inhibitssarscov2replicationinthesyrianhamstermodel AT kentbarbian orallydeliveredmk4482inhibitssarscov2replicationinthesyrianhamstermodel AT kimberlymeadewhite orallydeliveredmk4482inhibitssarscov2replicationinthesyrianhamstermodel AT atsushiokumura orallydeliveredmk4482inhibitssarscov2replicationinthesyrianhamstermodel AT shannaleventhal orallydeliveredmk4482inhibitssarscov2replicationinthesyrianhamstermodel AT davidwhawman orallydeliveredmk4482inhibitssarscov2replicationinthesyrianhamstermodel AT emilyricotta orallydeliveredmk4482inhibitssarscov2replicationinthesyrianhamstermodel AT catharinembosio orallydeliveredmk4482inhibitssarscov2replicationinthesyrianhamstermodel AT craigmartens orallydeliveredmk4482inhibitssarscov2replicationinthesyrianhamstermodel AT gregsaturday orallydeliveredmk4482inhibitssarscov2replicationinthesyrianhamstermodel AT heinzfeldmann orallydeliveredmk4482inhibitssarscov2replicationinthesyrianhamstermodel AT michaelajarvis orallydeliveredmk4482inhibitssarscov2replicationinthesyrianhamstermodel
_version_	1718378769342791680

Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model

Ejemplares similares